stockrow
Saturday 7 November 2026
Export HURA’s income statement to Excel — free account
TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
- EPS
- +33.3%
- Free cash flow
- −70.5%
Quarter to June 2026, against a year earlier
1.63
0.02
+1.24%
Follow HURA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 11 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (9) | (8) | (11) | (8) | (9) | (38) | (23) | (29) | (22) | (30) | (31) | +14.5% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (9) | (8) | (11) | (8) | (9) | (38) | (23) | (29) | (22) | (30) | (31) | +14.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (14,155.40) | (11,728.12) | (9,334.25) | (5,464.85) | (1,527.63) | (2,586.52) | (813.49) | (2.47) | (1.21) | (0.63) | (0.54) | (67.2%) | ||||||
| Cash flow | (8,576.33) | (11,455.86) | (8,209.08) | (4,218.27) | (1,321.33) | (1,274.32) | (730.90) | (1.01) | (0.79) | (0.58) | (0.46) | (65.6%) | ||||||
| Capex | (28.00) | (30.00) | (10.50) | 0.00 | 0.00 | (0.34) | 0.00 | (0.11) | 0.00 | 0.00 | 0.00 | (66.2%) | ||||||
| Free cash flow | (8,604.33) | (11,485.86) | (8,219.58) | (4,218.27) | (1,321.33) | (1,274.66) | (730.90) | (1.11) | (0.79) | (0.58) | (0.47) | (65.6%) | ||||||
| Book value | 8,098.00 | 9,397.86 | 4,529.33 | 1,311.67 | 43.83 | 714.93 | 422.76 | (0.13) | 0.78 | 0.44 | 0.29 | (66.4%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 19 | 48 | 56 | +250.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (8) | (10) | (6) | (8) | (19) | (20) | (12) | (15) | (28) | (30) | +20.5% | |||||
| Capex | 0 | 0 | 0 | — | — | 0 | — | (1) | 0 | 0 | 0 | +18.3% | ||||||
| Free cash flow | (5) | (8) | (10) | (6) | (8) | (19) | (20) | (13) | (15) | (28) | (30) | +20.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 6 | 7 | 5 | 2 | 0 | 9 | 9 | 1 | 14 | (1) | (8) | n/m | |||||
| Net debt | (6) | (7) | (6) | (4) | (2) | (11) | (12) | (1) | (13) | (4) | 8 | (5.7%) | ||||||
| Shareholders’ equity | 5 | 7 | 5 | 2 | 0 | 11 | 12 | (2) | 15 | 21 | 19 | +17.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (203.85) | (124.38) | (151.00) | (146.30) | (262.15) | (503.66) | (170.43) | (702.97) | (173.10) | (127.05) | (92.31) | +76.8 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (54,213.07) | (94,508.33) | 0.00 | (569.54) | (114.79) | (74.20) | (114.8) pt | ||||||
| ROE | 646.99 | 1,136.81 | 2,703.29 | 406.38 | 242.16 | 933.62 | 983.79 | 510.31 | (579.24) | (171.92) | (163.84) | (818.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 4 | 15 | 4 | 2 | 4 | 4 | 3 | 2 | 19 | 22 | — | +20.9% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
TuHURA Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| ANIX ANIXA BIOSCIENCES INC | $105.3M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NBP NovaBridge Biosciences | $105.3M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $102.9M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| HURA TuHURA Biosciences, Inc. | $102.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | |
| OKUR OnKure Therapeutics, Inc. | $102.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| Median of peers | $104.1M | — | — | −79.25% | — | +2.46% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 9 July 2026
Ownership
Directors and executive officers, together
6.06%
Vijay Patel
32.81%
Matthew Nachtrab
9.99%
Highbridge
8.69%
Samir Patel
5.63%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement